Skip to main content

Table 2 Comparative analysis of the clinicopathological findings between wild-type and mutated KRAS groups

From: Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis

Variables

KRAS

Wild-type

n = 34 (68.0%)

KRAS

Mutated

n = 16 (32.0%)

Univariate P*

Clinical factors

 Sex

  Male/female

19/15

10/6

0.763

 Age (years)

69 (32 − 81)

69 (47 − 84)

0.303

 CEA (ng/mL)

2.8 (0.4 − 133.1)

4.0 (1.0 − 116.6)

0.163

 CA19-9 (IU/mL)

65.0 (0.8 − 3055.0)

38.7 (0.7 − 766.0)

0.593

 Tumor size (cm)

  Radiographical

4.0 (1.0 − 13.0)

3.0 (1.0 − 14.0)

0.493

Treatment factors

 R0 resection, n (%)

33 (97.1)

15 (93.8)

0.542

 Minor hepatectomy, n (%)

4 (11.8)

2 (12.5)

1.000

 Morbidity

  C-D class III/IV, n (%)

9 (26.5)

3 (18.8)

0.728

 Preoperative chemotherapy

  Present, n (%)

0

0

0

 Adjuvant chemotherapy

  Present, n (%)

22 (64.7)

8 (50.0)

0.366

Pathological factors

 Tumor differentiation

  Well/moderate, n (%)

31 (91.2)

12 (75.0)

0.190

  Poor, n (%)

3 (8.8)

4 (25.0)

 

 GLUT-1 expression

1.0 (0.0 − 4.0)

4.0 (2.0 − 4.0)

< 0.001

 Vascular invasion

  Present, n (%)

22 (64.7)

12 (75.0)

0.533

 Bile duct invasion

  Present, n (%)

16 (47.1)

8 (50.0)

1.000

 Lymph node metastasis

  Present, n (%)

10 (29.4)

5 (31.3)

1.000

 Tumor number

  Multiple, n (%)

6 (17.6)

9 (56.3)

0.008

 Tumor size (cm)

  Pathological

3.6 (1.0 − 13.0)

3.4 (1.0 − 14.0)

0.532

 AJCC stage

  IV, n (%)

16 (47.1)

9 (56.3)

0.762

  1. AJCC American joint committee on cancer/international union against cancer classification, CA 19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, GLUT-1 glucose transporter-1, R0 resection no macroscopic and microscopic tumor remaining, C-D Clavien-Dindo classification system
  2. *Statistically significant differences (P < 0.05) are shown in italic